RIGVIR

RIGVIR (Riga virus) is a virotherapy medication approved by the State Agency of Medicines of the Republic of Latvia. It was developed in the 1960s and 1970s by the team of Aina Muceniece (1924–2010) and patented in 2002.

Rigvir is a drug containing a live and natural virus (ECHO-7) which has cytolytic and immunomodulating effects. Cytolytic action – finding and destroying malignant cells, applies only to the cancer cells without affecting the normal tissue cells.

RIGVIR was registered for treatment of cutaneous melanoma in Latvia on 29 April 2004, a few days before Latvia joined the European Union. Since Rigvir was registered via a national registration procedure, it has not been tested in the standard clinical trials required for central registration in the European Union.

Since Latvia is a member of European Union, according to Article 88 (DIRECTIVE 2001/83/EC on the Community code relating to medicinal products for human use), Member States shall prohibit the advertising to general public of medicinal products which are available on medical prescription only (page 26).

The most commonly reported side effects are subfebrile temperature, pain in the tumor, fatigue, drowsiness, and dyspepsia (diarrhea).

...
Wikipedia